Cargando…

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

Discovering biomarkers of drug response and finding powerful drug combinations can support the reuse of previously abandoned cancer drugs in the clinic. Indisulam is an abandoned drug that acts as a molecular glue, inducing degradation of splicing factor RBM39 through interaction with CRL4(DCAF15)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Pogacar, Ziva, Groot, Kelvin, Jochems, Fleur, Dos Santos Dias, Matheus, Mulero-Sánchez, Antonio, Morris, Ben, Roosen, Mieke, Wardak, Leyma, De Conti, Giulia, Velds, Arno, Lieftink, Cor, Thijssen, Bram, Beijersbergen, Roderick L, Bernards, René, Leite de Oliveira, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Life Science Alliance LLC 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095732/ https://www.ncbi.nlm.nih.gov/pubmed/35534224 http://dx.doi.org/10.26508/lsa.202101348

Ejemplares similares

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

The Cancer SENESCopedia: A delineation of cancer cell senescence
por: Jochems, Fleur, et al.
Publicado: (2021)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer
por: Jin, Haojie, et al.
Publicado: (2020)

A phase I and pharmacokinetic study of indisulam in combination with carboplatin
por: Dittrich, C, et al.
Publicado: (2007)

Importance of genetic screens in precision oncology
por: Mulero-Sánchez, Antonio, et al.
Publicado: (2019)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Inducing and exploiting vulnerabilities for the treatment of liver cancer
por: Wang, Cun, et al.
Publicado: (2019)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
por: Nijhuis, Anke, et al.
Publicado: (2022)

Indisulam Reduces Viability and Regulates Apoptotic Gene Expression in Pediatric High-Grade Glioma Cells
por: Monção, Caio C. D., et al.
Publicado: (2022)

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
por: Mulero‐Sánchez, Antonio, et al.
Publicado: (2023)

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality
por: Evers, Bastiaan, et al.
Publicado: (2014)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer
por: Zhou, Yangyang, et al.
Publicado: (2022)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1
por: Lu, Jiaqi, et al.
Publicado: (2023)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

The Histone Demethylase Jarid1b (Kdm5b) Is a Novel Component of the Rb Pathway and Associates with E2f-Target Genes in MEFs during Senescence
por: Nijwening, Jeroen H., et al.
Publicado: (2011)

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer
por: Guo, Yuchen, et al.
Publicado: (2021)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
por: Berns, Katrien, et al.
Publicado: (2018)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway
por: Mullenders, Jasper, et al.
Publicado: (2009)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
por: De Conti, Giulia, et al.
Publicado: (2021)

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling
por: Kuiken, Hendrik J, et al.
Publicado: (2012)

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
por: van der Noord, Vera E., et al.
Publicado: (2023)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
por: Llaurado Fernandez, Marta, et al.
Publicado: (2022)

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation
por: Smit, Linda, et al.
Publicado: (2015)

Targeting the RB-E2F pathway in breast cancer
por: Johnson, Jackie, et al.
Publicado: (2016)

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2023)

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Mammalian life depends on two distinct pathways of DNA damage tolerance
por: Buoninfante, Olimpia Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r2rf8u85v3035to84al98rkakt